Figure 5.
Figure 5. Expression of LV carrying a hepatocyte-specific promoter. (A) Confocal immunofluorescence analyses of liver sections immunostained for GFP, CD8, and TOPRO3 from C57BL/6 and BALB/c mice injected into the tail vein with LVs expressing the GFP marker from the ALB promoter; representative sections from 2 mice analyzed per time point per strain. Original magnification, × 400. (B) Quantitative real-time PCR of vector DNA from the liver and spleen DNA of injected mice at different times after injection. Means ± SD, n = 3, are shown. (C) FACS analysis of liver cell suspensions labeled with CD4 and CD8 antibodies from vector-injected mice and mice injected with vector particles without genome (pack) at different times after injection. The percentage of positive cells in the mononuclear cell gate (mean ± SD, n = 3) is shown.

Expression of LV carrying a hepatocyte-specific promoter. (A) Confocal immunofluorescence analyses of liver sections immunostained for GFP, CD8, and TOPRO3 from C57BL/6 and BALB/c mice injected into the tail vein with LVs expressing the GFP marker from the ALB promoter; representative sections from 2 mice analyzed per time point per strain. Original magnification, × 400. (B) Quantitative real-time PCR of vector DNA from the liver and spleen DNA of injected mice at different times after injection. Means ± SD, n = 3, are shown. (C) FACS analysis of liver cell suspensions labeled with CD4 and CD8 antibodies from vector-injected mice and mice injected with vector particles without genome (pack) at different times after injection. The percentage of positive cells in the mononuclear cell gate (mean ± SD, n = 3) is shown.

Close Modal

or Create an Account

Close Modal
Close Modal